Cue Biopharma, Inc.

Healthcare · Biotechnology · United States

Last price 20.87 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 151.61M

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

Cue Biopharma, Inc., a clinical-stage therapeutics company, focuses on developing various therapies for immunological disorders. The company’s lead asset is CUE-221, an anti-IgE antibody with a dual-mechanism of action currently in Phase 2 development for allergic diseases. It also developed the Immuno-STAT platform, which targets disease-specific T cells in vivo without broad immune modulation. The company’s lead autoimmune candidate is CUE-401, a bifunctional IL-2 and TGF-B program that is advancing towards Phase 1 development to regulate inf...